Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 6
2007 9
2008 17
2009 11
2010 11
2011 20
2012 35
2013 45
2014 46
2015 69
2016 66
2017 56
2018 42
2019 38
2020 59
2021 43
2022 38
2023 28
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

526 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators. Schüpke S, et al. N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475799 Clinical Trial.
BACKGROUND: The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. ...Definite or probable stent thrombosis occurred in 1.3% of patients assigned to ticagrelor and 1.0% o …
BACKGROUND: The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive …
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Wiviott SD, et al. N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4. N Engl J Med. 2007. PMID: 17982182 Free article. Clinical Trial.
RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant …
RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel
Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Shah RP, Shafiq A, Hamza M, Maniya MT, Duhan S, Keisham B, Patel B, Alamzaib SM, Yashi K, Uppal D, Sattar Y, Tiwari D, Paul TK, AlJaroudi W, Alraies MC. Shah RP, et al. Am J Cardiol. 2023 Nov 15;207:206-214. doi: 10.1016/j.amjcard.2023.08.117. Epub 2023 Sep 24. Am J Cardiol. 2023. PMID: 37751668 Review.
Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available. ...The overall mean age was 62.73 years, whereas the mean age for the ticagrelor and prasugrel groups was 63.80 and 61.65 years, respectively. Prasugrel is equally effec …
Limited data comparing prasugrel and ticagrelor in acute coronary syndrome are available. ...The overall mean age was 62.73 years, wh …
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Gimbel M, et al. Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1. Lancet. 2020. PMID: 32334703 Clinical Trial.
We aimed to investigate the safety and efficacy of clopidogrel compared with ticagrelor or prasugrel in older patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). ...FINDINGS: Between June 10, 2013, and Oct 17, 2018, 1002 patients were randomly assigned to cl …
We aimed to investigate the safety and efficacy of clopidogrel compared with ticagrelor or prasugrel in older patients with non-ST-el …
Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Al-Abdouh A, Barbarawi M, Abusnina W, Amr M, Zhao D, Savji N, Hasan RK, Michos ED. Al-Abdouh A, et al. Cardiovasc Revasc Med. 2020 Dec;21(12):1613-1618. doi: 10.1016/j.carrev.2020.05.038. Epub 2020 May 28. Cardiovasc Revasc Med. 2020. PMID: 32513604 Review.
INTRODUCTION: Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor added to aspirin is considered the standard of care for patients with acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). Prasugrel and ticagrelor are commonly used P2Y12 inhibitors …
INTRODUCTION: Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor added to aspirin is considered the standard of care for patients with …
Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.
Zhang H, Zhang P, Dong P, Yang X, Wang Y, Zhang H, Yan J, Zhang Y, Zhang T, Li Y. Zhang H, et al. Coron Artery Dis. 2017 Nov;28(7):597-604. doi: 10.1097/MCA.0000000000000541. Coron Artery Dis. 2017. PMID: 28968313 Review.
For the loading dose, using the VerifyNow-P2Y12 (VN) test, the PR was similar for both the prasugrel and ticagrelor groups [MD=10.80 (-9.81-31.40), P=0.30]. Using the vasodilatorstimulated phosphoprotein test, the PR was also similar for both the ticagrelor and prasugre
For the loading dose, using the VerifyNow-P2Y12 (VN) test, the PR was similar for both the prasugrel and ticagrelor groups [MD=10.80 …
Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: A meta-analysis.
Xia P, He C, Chen L, Zou L, Sun S, Cui P, Wang W. Xia P, et al. J Neurol Sci. 2019 Feb 15;397:174-178. doi: 10.1016/j.jns.2019.01.005. Epub 2019 Jan 8. J Neurol Sci. 2019. PMID: 30641247 Review.
BACKGROUND: Prasugrel as a second generation P2Y12 adenosine diphosphate receptor antagonist which in the cerebral aneurysms with Endovascular treatment have become more emphasized. OBJECTIVE: To compare the efficacy and safety of prasugrel therapy for intracranial …
BACKGROUND: Prasugrel as a second generation P2Y12 adenosine diphosphate receptor antagonist which in the cerebral aneurysms with End …
Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY. Rodriguez AE, et al. Curr Pharm Des. 2018;24(4):465-477. doi: 10.2174/1381612824666180108121834. Curr Pharm Des. 2018. PMID: 29308737 Review.
Direct comparisons of prasugrel and ticagrelor from large RCT are not yet available, however, several observational registries and metaanalysis reported results from an indirect comparison between both compounds. ...Compared to ticagrelor, prasugrel appears to be mo …
Direct comparisons of prasugrel and ticagrelor from large RCT are not yet available, however, several observational registries and me …
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Verdoia M, Barbieri L, Suryapranata H, De Luca G. Verdoia M, et al. Platelets. 2016;27(2):93-104. doi: 10.3109/09537104.2015.1042447. Epub 2015 May 13. Platelets. 2016. PMID: 25970631 Review.
Conclusive data on the strategy of switching from Clopidogrel to Prasugrel are still missing, therefore we aimed to perform a meta-analysis of current studies evaluating the safety and efficacy of switching from Clopidogrel to Prasugrel (PS) as compared to a standar …
Conclusive data on the strategy of switching from Clopidogrel to Prasugrel are still missing, therefore we aimed to perform a meta-an …
Meta-Analysis Comparing the Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome.
Ullah W, Ali Z, Sadiq U, Rafiq A, Khan S, Mamas MA, Sabouret P, Fischman DL. Ullah W, et al. Am J Cardiol. 2020 Oct 1;132:22-28. doi: 10.1016/j.amjcard.2020.07.017. Epub 2020 Jul 17. Am J Cardiol. 2020. PMID: 32771221 Review.
Prasugrel and ticagrelor are preferred over clopidogrel for patients with acute coronary syndrome who underwent percutaneous coronary intervention. ...In conclusion, prasugrel might have lower odds of MACCE and mortality at 30 days. ...
Prasugrel and ticagrelor are preferred over clopidogrel for patients with acute coronary syndrome who underwent percutaneous coronary
526 results